[Novo Nordisk sign on building, Danish pharmaceutical healthcare giant, production innovative drugs, obesity treatment Ozempic, pharmaceutical company innovation, Mainz, Germany June 15, 2024] Victor Golmer Jiangsu Hengrui Pharmaceuticals has agreed to license global rights to its experimental obesity drug HRS-1596 to Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) in a deal worth up to $2.6B. Under the agreement, Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) will receive exclusive rights to develop, manufacture, and commercialize HRS-1596 globally, excluding mainland China, Hong Kong, Macau, and Taiwan.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.